



## Syntheses of isocitric acid derivatives and biological evaluation

Motoo Tori,<sup>a,\*</sup> Yoko Sono,<sup>a</sup> Yasuyo Nakashiba,<sup>a</sup> Noriko Hamada,<sup>a</sup> Masakazu Sono,<sup>a</sup>  
Yoshinori Asakawa,<sup>a,\*</sup> Masami Suganuma,<sup>b</sup> Sachiko Okabe<sup>b</sup> and Hirota Fujiki<sup>b</sup>

<sup>a</sup>Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro cho, Tokushima 770-8514, Japan

<sup>b</sup>Saitama Cancer Center Research Institute, Ina, Kitaadachi-gun, Saitama 362-0806, Japan

Received 17 January 2000; accepted 17 February 2000

### Abstract


Isocitric acid methyl esters and their derivatives have been synthesized and their biological activities, superoxide release inhibition and tumor necrosis factor- $\alpha$  (TNF $\alpha$ )'s release inhibition, have been studied. Linoleic and linolenic acid derivatives showed strong activity against TNF $\alpha$ 's release inhibition comparable to sarcophytol A and cryptoporic acid E. © 2000 Elsevier Science Ltd. All rights reserved.

**Keywords:** biologically active compounds; carboxylic acids and derivatives; esters; terpenes and terpenoids.

We have previously reported the isolation of cryptoporic acids A–F from the fungus *Cryptoporus volvatus* and established their structures based on high resolution 2D NMR techniques, X-ray analysis, and chemical degradations.<sup>1–5</sup> It is very interesting to note that cryptoporic acids exhibit strong superoxide release inhibition and anti-tumor promotion activities.<sup>5</sup> The structures are unusual; namely, they are drimane-type sesquiterpenes linked to isocitric acid moiety with an ether bond.<sup>6–10</sup> We were interested in their biological activities and planned to prepare synthetic substitutes to the natural products.<sup>11</sup> We first intended to prepare isocitric acid with the same stereochemistry as natural products. Then fatty acids were attached to the isocitric acid and biological activities of these esters were evaluated. We now report our preliminary results.


Since Seebach et al. reported the alkylation of malic acid and synthesis of isocitric acid,<sup>12</sup> we have modified their methodology to prepare monocarboxylic acid derivatives<sup>13</sup> (Scheme 1). The allylated compound **2** of (*R*)-(+)- or racemic malic acid was protected with the MOM group and subjected to ozonolysis. The Jones' oxidation of aldehyde **4** afforded acid **5**, which was converted to trichloroethyl ester **6** using DCC. The MOM group was deprotected by TMSBr and fatty acids were used for the preparation of esters, whose trichloroethyl group was removed under Zn–AcOH–MeOH conditions to afford **8**, **9** and **10**.<sup>14</sup> Trimethyl isocitrate (**11**)<sup>14</sup> was synthesized by methylation (CH<sub>2</sub>N<sub>2</sub>) of acid **5** and deprotection of the MOM group in 65% yield from **5**.

\* Corresponding authors. Tel: +81-88-622-9611; fax: +81-88-655-3051; e-mail: tori@ph.bunri-u.ac.jp (M. Tori), asakawa@ph.bunri-u.ac.jp (Y. Asakawa)



Scheme 1. *Reagents and conditions:* (a) LDA, BrCH<sub>2</sub>CH=CH<sub>2</sub>; (b) MOM-Cl, EtN<sup>i</sup>Pr<sub>2</sub>; (c) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>-MeOH, then SMe<sub>2</sub>; (d) Jones; (e) DCC, HOCH<sub>2</sub>CCl<sub>3</sub>, DMAP; (f) BrSiMe<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (g) RCOOH, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (h) Zn, AcOH, MeOH

Malic acid derivatives were similarly prepared (Scheme 2). The MOM-protected methyl glycolate was allylated, and similarly converted to methyl trichloroethyl ester of the malic acid **15**. The esterification with fatty acids using DCC and deprotection afforded **16** and **17**.<sup>14</sup>



Scheme 2. *Reagents and conditions:* (a) LDA, BrCH<sub>2</sub>CH=CH<sub>2</sub>; (b) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>-MeOH, then SMe<sub>2</sub>; (c) Jones; (d) DCC, HOCH<sub>2</sub>CCl<sub>3</sub>, DMAP; (e) BrSiMe<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (f) RCOOH, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (g) Zn, AcOH, MeOH

Because the natural products exhibit strong superoxide release inhibition activities,<sup>4,5</sup> these compounds were subjected to the same tests.<sup>4,5</sup> The results are listed in Table 1.<sup>15</sup> Among those tested, compound **16** was the most effective (IC<sub>50</sub> 0.39 μM). The malic acid derivatives were 10 times more effective than isocitric acid derivatives. The linoleic acid derivatives were more than twice as strong as linolenic acid derivatives.

Compounds **8** and **9** were further subjected to inhibition tests of TNFα's release with okadaic acid by anti-tumor promoters on BALB/3T3 cells.<sup>5,16</sup> As shown in Fig. 1, both compounds are as strong as sarcophytol A (**18**) and cryptoporin acid E (**19**). Therefore, it is very interesting to note that the relative positions of the hydrophilic and lipophilic parts are very important, and that the lipophilic part can be substituted by fatty acids to show anti-tumor promoter activity.

Thus, we have prepared fatty acid derivatives with isocitric and malic acid moiety and evaluated their biological activities, and two of them (**8** and **9**) were as effective as sarcophytol A (**18**) and cryptoporin acid E (**19**) in inhibition of TNFα's release.

Table 1  
Superoxide release inhibition activity against guinea pig macrophage





Fig. 1. Inhibition of TNF $\alpha$ 's release with okadaic acid by anti-tumor promoters on BALB/3T3 cells

## Acknowledgements

We thank Dr. T. Nishi and Otsuka Pharmaceutical Co. Ltd., for carrying out biological tests. We are also grateful to Dr. M. Tanaka and Miss Y. Okamoto, Tokushima Bunri University, for measurements of 600 MHz NMR and MS spectra, respectively.

## References

1. Hashimoto, T.; Tori, M.; Mizuno, Y.; Asakawa, Y. *Tetrahedron Lett.* **1987**, *28*, 6303–6304.
2. Hashimoto, T.; Tori, M.; Asakawa, Y. *Trans. Mycol. Soc. Japan* **1988**, *29*, 281–296.
3. Hashimoto, T.; Tori, M.; Mizuno, Y.; Asakawa, Y.; Fukazawa, Y. *J. Chem. Soc., Chem. Commun.* **1989**, 258–259.
4. Asakawa, Y.; Hashimoto, T.; Mizuno, Y.; Tori, M.; Fukazawa, Y. *Phytochemistry* **1992**, *31*, 579–592.
5. Hashimoto, T.; Asakawa, Y. *Heterocycles* **1998**, *47*, 1067–1110.
6. Hayashi, N.; Mikata, K.; Yasuda, S.; Komae, H. *The 31st Symposium on Terpene and Essential Oil*, Symposium Paper, 1987; pp. 59–60.
7. Hirotani, M.; Furuya, T.; Shiro, M. *Phytochemistry* **1991**, *30*, 1555–1559.
8. Hirotani, M.; Ino, C.; Furuya, T. *Phytochemistry* **1993**, *32*, 891–896.
9. Takahashi, H.; Toyota, M.; Asakawa, Y. *Phytochemistry* **1993**, *33*, 1055–1059.
10. Nozoe, S.; Agatsuma, T.; Takahashi, A. *Tetrahedron Lett.* **1993**, *34*, 2497–2500.
11. Cryptoporic acid A methyl ester has been synthesized by the use of 1,4-addition reaction; cf. the following paper.
12. Seebach, D.; Aebi, J.; Wasmuth, D. *Org. Synth.* **1984**, *63*, 109–120.
13. Schmitz, C.; Rouanet-Dreyfuss, A.; Tueni, M.; Biellmann, J. *Tetrahedron Lett.* **1992**, *33*, 4911–4912; *J. Org. Chem.* **1996**, *61*, 1817–1821.
14. Established by the spectral data: IR,  $^1\text{H}$  and  $^{13}\text{C}$  NMR, MS, and HRMS.
15. The inhibition of the release of superoxide anion radical from guinea pig peritoneal macrophage induced by  $\text{O}_2^-$  stimulant FMLP (formyl methionyl leucyl phenylalanine:  $10^{-7}$  M) was measured.
16. Komori, A.; Yatsunami, J.; Sugauma, M.; Okabe, S.; Abe, S.; Sakai, A.; Sasaki, K.; Fujiki, H. *Cancer Res.* **1993**, *53*, 1982–1985.